CL2016000028A1 - Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación - Google Patents

Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación

Info

Publication number
CL2016000028A1
CL2016000028A1 CL2016000028A CL2016000028A CL2016000028A1 CL 2016000028 A1 CL2016000028 A1 CL 2016000028A1 CL 2016000028 A CL2016000028 A CL 2016000028A CL 2016000028 A CL2016000028 A CL 2016000028A CL 2016000028 A1 CL2016000028 A1 CL 2016000028A1
Authority
CL
Chile
Prior art keywords
inhalation
dry powder
anticholinergic
corticosteroid
adrenergic
Prior art date
Application number
CL2016000028A
Other languages
English (en)
Inventor
Rossella Musa
Irene Pasquali
Azita Askey-Sarvar
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of CL2016000028A1 publication Critical patent/CL2016000028A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACION EN POLVO SECO PARA USAR EN INHALADOR QUE COMPRENDE: A) PARTICULAS FINAS DE ESTEARATO DE MAGNESIO, B) PARTICULAS GRUESAS DE UN EXCIPIENTE Y C) PARTICULAS MICRONIZADAS DE UN ANTICOLINERGICO, UN CORTICOTEROIDE PARA INHALACION (ICS) Y UN AGONISTA B2 DE ACCION PROLONGADA (LABA); PROCESO PARA PREPARARLA; Y DISPOSITIVO.
CL2016000028A 2013-07-11 2016-01-08 Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación CL2016000028A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28

Publications (1)

Publication Number Publication Date
CL2016000028A1 true CL2016000028A1 (es) 2016-08-05

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000028A CL2016000028A1 (es) 2013-07-11 2016-01-08 Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación

Country Status (36)

Country Link
US (2) US9402825B2 (es)
EP (3) EP3569222B1 (es)
JP (1) JP6426167B2 (es)
KR (2) KR20160029797A (es)
CN (1) CN105338960B (es)
AR (1) AR129501A2 (es)
AU (1) AU2014289185B2 (es)
BR (1) BR112015030914B1 (es)
CA (1) CA2917752C (es)
CL (1) CL2016000028A1 (es)
CY (2) CY1120806T1 (es)
DK (3) DK3019153T3 (es)
EA (1) EA029125B1 (es)
ES (2) ES2699986T3 (es)
FI (1) FI3569222T3 (es)
GE (1) GEP20186853B (es)
HK (1) HK1218712A1 (es)
HR (2) HRP20182008T1 (es)
HU (2) HUE053957T2 (es)
IL (1) IL243507A0 (es)
LT (3) LT3569222T (es)
MX (1) MX2016000290A (es)
MY (1) MY176176A (es)
NZ (1) NZ715797A (es)
PE (2) PE20212110A1 (es)
PH (1) PH12016500043A1 (es)
PL (2) PL3019153T3 (es)
PT (1) PT3019153T (es)
RS (2) RS61652B1 (es)
SA (1) SA516370373B1 (es)
SG (1) SG11201600110RA (es)
SI (2) SI3409270T1 (es)
TN (1) TN2016000007A1 (es)
TW (1) TWI642450B (es)
UA (1) UA116907C2 (es)
WO (1) WO2015004243A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160853A1 (es) * 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
RS63706B1 (sr) * 2012-01-25 2022-11-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
PL3019153T3 (pl) * 2013-07-11 2019-02-28 Chiesi Farmaceutici S.P.A. Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
JP6600961B2 (ja) * 2015-03-30 2019-11-06 ブラザー工業株式会社 表示制御装置、表示制御方法及び記憶媒体
CA2983427C (en) * 2015-05-01 2024-04-23 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
HUE056402T2 (hu) 2015-11-16 2022-02-28 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
DK3620176T3 (da) 2015-11-16 2021-09-20 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
DE202017007661U1 (de) * 2016-11-10 2024-02-21 Medisca Pharmaceutique Inc. System zur pharmazeutischen Zubereitung
BR112019023386A2 (pt) * 2017-05-11 2020-06-16 Chiesi Farmaceutici S.P.A. Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco
US10786450B2 (en) * 2017-05-11 2020-09-29 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
EP4034079A1 (en) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Novel carrier particles for dry powder formulations for inhalation
US12029709B2 (en) * 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
AU6926101A (en) * 2000-06-27 2002-01-08 Vectura Ltd Method of making particles for use in a pharmaceutical composition
EP1920763B2 (en) * 2000-11-30 2022-06-15 Vectura Limited Pharmaceutical compositions for inhalation
PT1658872E (pt) 2002-07-31 2011-05-12 Chiesi Farma Spa Inalador de p?
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
PE20160853A1 (es) * 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
WO2011120779A1 (en) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
EP2560611B1 (en) * 2010-04-21 2018-01-03 Chiesi Farmaceutici S.p.A. "process for providing particles with reduced electrostatic charges"
WO2011160920A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
RS63706B1 (sr) * 2012-01-25 2022-11-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PL3019153T3 (pl) * 2013-07-11 2019-02-28 Chiesi Farmaceutici S.P.A. Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny do podawania wziewnego

Also Published As

Publication number Publication date
ES2867552T3 (es) 2021-10-20
HRP20182008T1 (hr) 2019-01-25
BR112015030914A2 (es) 2017-07-25
KR102275904B1 (ko) 2021-07-13
SA516370373B1 (ar) 2017-10-11
GEP20186853B (en) 2018-05-25
NZ715797A (en) 2020-06-26
ES2699986T3 (es) 2019-02-13
TN2016000007A1 (en) 2017-07-05
PH12016500043B1 (en) 2016-03-28
CN105338960B (zh) 2019-06-04
BR112015030914B1 (pt) 2023-04-04
US20150017248A1 (en) 2015-01-15
TW201536352A (zh) 2015-10-01
CN105338960A (zh) 2016-02-17
PL3019153T3 (pl) 2019-02-28
PE20212110A1 (es) 2021-11-04
EP3409270A1 (en) 2018-12-05
US9808422B2 (en) 2017-11-07
EA029125B1 (ru) 2018-02-28
AU2014289185B2 (en) 2019-05-23
EP3019153B1 (en) 2018-09-05
PL3409270T3 (pl) 2021-08-09
TWI642450B (zh) 2018-12-01
MX2016000290A (es) 2016-04-13
UA116907C2 (uk) 2018-05-25
WO2015004243A1 (en) 2015-01-15
SI3409270T1 (sl) 2021-07-30
DK3569222T3 (da) 2024-08-19
CA2917752A1 (en) 2015-01-15
CY1120806T1 (el) 2019-12-11
HUE053957T2 (hu) 2021-08-30
IL243507A0 (en) 2016-02-29
JP2016523950A (ja) 2016-08-12
EA201690006A1 (ru) 2016-07-29
KR20160029797A (ko) 2016-03-15
EP3569222A1 (en) 2019-11-20
DK3409270T3 (da) 2021-04-26
AR129501A2 (es) 2024-09-04
PT3019153T (pt) 2018-12-04
KR20210075217A (ko) 2021-06-22
HUE039827T2 (hu) 2019-02-28
SI3019153T1 (sl) 2018-12-31
CY1123937T1 (el) 2022-05-27
EP3569222B1 (en) 2024-06-26
EP3019153A1 (en) 2016-05-18
US9402825B2 (en) 2016-08-02
DK3019153T3 (en) 2018-11-19
MY176176A (en) 2020-07-24
HRP20210704T1 (hr) 2021-06-11
FI3569222T3 (fi) 2024-09-24
LT3569222T (lt) 2024-09-25
RS61652B1 (sr) 2021-04-29
AU2014289185A1 (en) 2016-02-04
LT3409270T (lt) 2021-07-26
RS57799B1 (sr) 2018-12-31
CA2917752C (en) 2022-05-03
PH12016500043A1 (en) 2016-03-28
PE20160372A1 (es) 2016-05-19
SG11201600110RA (en) 2016-02-26
HK1218712A1 (zh) 2017-03-10
EP3409270B1 (en) 2021-02-24
JP6426167B2 (ja) 2018-11-21
LT3019153T (lt) 2018-11-26
US20160263027A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
CL2016000028A1 (es) Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación
CO2017004649A2 (es) Esteroides neuroactivos para trastornos del snc
AR098640A1 (es) Inhalador de polvo seco
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
CL2015002632A1 (es) Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado
BR112018070199A2 (pt) composição farmacêutica de hormônio esteroide
CR20150326A (es) Inhibidores de autotaxina
CL2016000735A1 (es) Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc.
CL2015002787A1 (es) Formulación de acetato de abiraterona.
GT201400182A (es) Formulaciones farmacéuticas novedosas
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
DOP2015000284A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
AR093382A1 (es) Dispositivo de administracion de farmacos para el tratamiento de pacientes con enfermedades respiratorias
MD3377108T2 (ro) Procedeu de obţinere a unei formulări de pulbere uscată ce conţine un anticolinergic, un corticosteroid și un beta-adrenergic
BR112015025814A2 (pt) composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação
AR099364A1 (es) Inhalador de medicamentos
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
CL2016001436A1 (es) Formas de dosificación farmacéuticas
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
ES2662847T3 (es) Formulaciones novedosas de inhalación
UY35526A (es) Derivados de espiroindolina y composiciones farma céuticas de los mismos
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations